2018 Guideline on the Management of Blood Cholesterol

This is the document that most American clinicians reach for when they decide whether to lower your cholesterol, and how aggressively. Endorsed by twelve organizations and downloaded more than 1.7 million times, the 2018 cholesterol guideline is as close to the standard of care as a single paper gets.

Its core architecture is risk-based. Rather than treating a number in isolation, it sorts patients into groups — those with established disease, those with LDL above 190, those with diabetes, and everyone else stratified by estimated 10-year risk — and matches statin intensity to the danger. For the highest-risk patients it introduces a “very high-risk” category and a clear escalation: high-intensity statin, then ezetimibe, then a PCSK9 inhibitor if LDL stays above 70.

Two updates from the 2013 version matter most for early detection. The guideline gives coronary artery calcium scoring a formal role as a tie-breaker for patients in the borderline and intermediate zone — a CAC of zero can justify holding off, a high score argues for treating. And it broadens the list of risk-enhancing factors, including lipoprotein(a), that should push a wavering decision toward therapy.

The fair criticism is its conservatism on targets. It largely retained percentage-reduction goals rather than committing to specific LDL numbers, and its statin-first framing arrived just as the evidence for getting LDL much lower — and for measuring apolipoprotein B rather than LDL alone — was strengthening. The European guidelines of the following year went further.

We rate the evidence very strong. It is rigorous, comprehensive, and broadly endorsed — the practical foundation of lipid management in the United States, even where the science has since pressed past it.